Real world effectiveness of Ledipasvir/Sofosbuvir based regimens in hepatitis C virus genotype 1,2 and 3 infection within national hepatitis C elimination program in the country of Georgia

Twelve weeks of ledipasvir/sofosbuvir all‐oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials

“…As part of the elimination program, which aims to reduce the HCV prevalence by 90% (to 0.5%) by 2020, 20066 patients have been treated with LDV/SOF± RBV, and the overall SVR across genotypes 1-3 was 98%. 41 In 2016, the fixed dose combination of SOF and velpatasvir (VEL) was approved as a pan-genotypic DAA regimen first in the USA, and it was then recommended for HCV elimination by the WHO in 2019, given its high SVR12 rates regardless of genotype, treatment experience, and cirrhosis status. 42 Depending on region and health-care system, LDV/SOF and SOF/VEL, both with proven efficacy and safety profiles, might play complimentary roles.…”

“…In 2015,the anti‐HCV prevalence in Georgia was estimated at 7.7%, with genotypes 1, 2, and 3 accounting for 41%, 25%, and 34% of HCV infections, respectively. As part of the elimination program, which aims to reduce the HCV prevalence by 90% (to 0.5%) by 2020, 20 066 patients have been treated with LDV/SOF ± RBV, and the overall SVR across genotypes 1–3 was 98% 41 . In 2016, the fixed dose combination of SOF and velpatasvir (VEL) was approved as a pan‐genotypic DAA regimen first in the USA, and it was then recommended for HCV elimination by the WHO in 2019, given its high SVR12 rates regardless of genotype, treatment experience, and cirrhosis status 42 .…”